Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company focused on developing MasterKey therapies that target families of oncogenic mutations. The company aims to expand the addressable patient population by offering one solution for many mutations, thereby addressing cancer resistance and improving patient outcomes. Black Diamond Therapeutics is advancing two potent, brain-penetrant clinical-stage programs: BDTX-1535, a fourth-generation EGFR inhibitor targeting non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a RAF inhibitor targeting KRAS, NRAS, and BRAF alterations in NSCLC and other solid tumors. The company operates in the oncology market, serving patients with various types of cancer. Its business model involves the development and clinical testing of targeted therapies, with revenue generated through partnerships, licensing agreements, and eventual product sales. Black Diamond Therapeutics is committed to providing people living with cancer the opportunity to experience longer, healthier, and more active lives.

Keywords: oncology, MasterKey therapies, oncogenic mutations, clinical-stage, EGFR inhibitor, RAF inhibitor, NSCLC, glioblastoma, solid tumors, cancer resistance.